Long-term follow-up of complete remission in a patient with advanced hepatocellular carcinoma treated with sorafenib: a case report

Znanstveni rad - Izvorni znanstveni rad

• Autor: Gordan Adžić
• Autor: Juraj Prejac
• Autor: Stjepko Pleština
• Autorova ustanova: (Klinički bolnički centar Zagreb)
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet
• Autorova ustanova: Sveučilište u Zagrebu; Stomatološki fakultet
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti

Sažetak (engleski)

Introduction: Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancer and can be caused by well-known risk factors, including infection with hepatitis B and C viruses, alcohol intake, and metabolic syndrome. The overall prognosis remains poor with a median survival of 1 year for symptomatic advanced-stage cases treated with systemic therapies. Case description In July 2020, a 73-year-old male patient presented at our institution with mild abdominal pain and an attack of intense cold. After a radiological workup, the diagnosis of HCC located in the caudate lobe was established. The patient underwent atypical caudate lobe resection, and pathology confirmed the diagnosis of grade 3 HCC. Postoperative MRI showed a new metastasis in the 6th liver segment 1.3 cm in diameter, and a PVT progression which now affected the whole right lobe. The patient was started on sorafenib and demonstrated a complete response which still lasts for more than two years. Conclusion: We present a rare case of a patient who demonstrated a complete response to sorafenib treatment in advanced HCC with unfavorable prognostic factors.

• Ključne riječi (engleski): hepatocellular carcinoma; sorafenib; complete response; tyrosine-kinase inhibitor; case report
• Jezik: engleski
• Vrsta publikacije: Znanstveni rad - Izvorni znanstveni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran - međunarodna recenzija
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: Frontiers in Oncology
• Brojčani podaci: vol. 13, 1260989
• e-ISSN: 2234-943X
• DOI: https://doi.org/10.3389/fonc.2023.1260989
• URN:NBN: urn:nbn:hr:127:515500
• Datum objave publikacije: 2023-10-10
• URL dokumenta: https://www.frontiersin.org/articles/10.3389/fonc.2023.1260989/full
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2024-07-02 11:20:01